Stockreport

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety ...

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com
PDF An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhib [Read more]